All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Bookmark this article
On April 23, 2021, it was announced that the U.S. Food and Drug Administration (FDA) approved the use of loncastuximab tesirine-lpyl, an antibody–drug conjugate (ADC), for the treatment of adult patients with relapsed and refractory (R/R) large B-cell lymphoma who have had ≥2 lines of therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high grade B-cell lymphoma.1 This approval was based on the results of the phase II LOTIS-2 trial (NCT03589469), previously reported on the Lymphoma Hub.
Loncastuximab tesirine-Ipyl is a CD19-targeted antibody and alkylating agent conjugate designed to target and kill CD19-expressing malignant B cells. LOTIS-2 is a single-arm, multicenter trial in 145 adult patients with R/R diffuse large B-cell lymphoma (DLBCL) who received ≥2 prior lines of systemic therapy. Treatment with loncastuximab tesirine-Ipyl resulted in an overall response rate of 48.3% and a complete response rate of 24.1%. The median duration of response was 10.3 months. The most common Grade ≥3 treatment-emergent adverse events (in ≥10% of patients) included neutropenia (26.2%), thrombocytopenia (17.9%), increased gamma-glutamyltransferase (17.2%), and anemia (10.3%).
This approval is the first for an CD19-targeted ADC as single-agent therapy for R/R DLBCL.1
On May 5, 2021, loncastuximab tesirine-lpyl was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for the treatment of B-cell lymphomas. As a result, the agent now represents a category 2A treatment option for patients with DLBCL who have relapsed following ≥2 lines of systemic therapy.2
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Loncastuximab tesirine in relapsed or refractory DLBCL: Results from a phase II trial
The CD19-targeted antibody–drug conjugate, loncastuximab tesirine, was recently added to the National Comprehensive Cancer Network (NCCN) Clinical Practice...
Loncastuximab tesirine granted priority review status by the FDA
On November 20, 2020, the U.S. Food and Drug Administration (FDA) accepted the biologics license application (BLA) for loncastuximab tesirine for the treatment of patients with relapsed...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox